期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CK19、34βE12、E-cadherin在甲状腺乳头状癌组织中的表达及临床病理学意义 被引量：4

下载PDF
导出
摘要 甲状腺癌是头颈部比较常见的恶性肿瘤，占全身恶性肿瘤的1％-2％，女性多见，其发病率近年来呈上升趋势，绝大多数都发生在青壮年。甲状腺乳头状癌（PTC）是甲状腺恶性肿瘤中发病率最高的一种类型，约占60％-70％，平均发病年龄40岁，且女性多于男性，女与男之比为203：1。肿瘤国际组织学分类将PTC界定为：“甲状腺具有明确的滤泡细胞分化，典型的乳头及滤泡结构，
作者 王新杰 李清怀
机构地区 承德市中心医院肿瘤科 河北医科大学附属第二医院外科
出处 《承德医学院学报》 2007年第4期411-413,共3页 Journal of Chengde Medical University
关键词 CK19、34 β E12、E-cadherin 甲状腺乳头状癌 蛋白表达 免疫组化
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1杨洁清 周秀荣.198例甲状腺癌临床病理分析.诊断病理学杂志,1999,6:1071-1071.
  • 2CHeung CC,Ezza TS,Freeman JL.Immunohistochemical diagnosis of papillary thyroid carcinoma[J].Mod Pathol, 2001,14(4): 338-342.
  • 3Bondenmuller H,Banauch D.Technical evaluation of a new automated tumor marker assay;the Enzymun-test CYFRA21-1 [A].In:Klapdor R.Tumor associated antigens, oncogenes,rceptors,cytokinesint-Umo diagnosis and therapy at the beginning of the 90th[M].Zucksc-hwerdt Verlag, 1992.137-138.
  • 4张静,丘钜世,陈金培,李雯,刘国荣.CK19、CK20在甲状腺乳头状癌诊断中的应用价值[J].临床与实验病理学杂志,2002,18(2):181-184. 被引量：24
  • 5周炜洵,肖雨,刘彤华,罗玉凤,曹金伶.细胞角蛋白和Ret蛋白在甲状腺乳头状癌中的表达[J].中华病理学杂志,2003,32(6):530-533. 被引量：14
  • 6Cheung CC,Ezzat S,Free man JL,et al.Immunohistochemical diagnosis of papillary thyroid carcinoma [J].Mod Pathol,2001,14: 338-342.
  • 7陈晓东,周本成,赖日权,田野,冼江.细胞角蛋白表达在甲状腺乳头状癌诊断中的应用[J].诊断病理学杂志,2003,10(1):25-26. 被引量：20
  • 8Rapheal SJ,Mckeown-Eyssen G,Asa SL.High-molecularweight cytokeratin and cytokeratinl 9 in the diagnosis of thyroid tumor [J].Mod Pathol, 1994,7:295 - 301.
  • 9Baloch ZW,Abraham S,Roberts S,et al.Differential expression of cytokeratins in follicular variant of papillary carcinoma:an immunohistochemical study and its diagnostic utility[J].Hum Pathol, 1999,30(10): 1166.
  • 10余永伟,马大烈,郑青渝,张顺民,黄玲,詹洲.高分子量角蛋白抗体(34βE_(12))在前列腺癌诊断中的应用价值[J].临床与实验病理学杂志,1999,15(2):112-114. 被引量：13

二级参考文献15

  • 1中山医科大学 同济医科大学.外科病理学，第2版[M].武汉:湖北科学技术出版社,1998.1299-304.
  • 2[1]Rosai J, Carcangin ML, Delellis RA. Atlas of tumor pathology: tumors of the thyroid gland. AFIP 3rd series, Fascicle 5,1992. 100
  • 3[2]Hedinger Chr, Williams ED, Sobin LH. Histological typing of thyroid tumor. 2nd ed, New York:Springer, 1998
  • 4[3]Baloch ZW, Abraham S, Roberts S et al. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum Pathol, 1999, 30:1166
  • 5[4]Nasser SM, Pitman MB, Pilch BZ et al. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining. Cancer, 2000,90:307
  • 6[5]Miettinen M, Kovatich AJ, Karkkainen P. Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications. Virchows Arch, 1997,431:407
  • 7Liberman E, Weidner N. Papillary and follicular neoplasms of the thyroid gland. Differental immunohistochemical staining with high-molecular-weight keratin and involucrin. Appl Immunohistochem Mol Morphol, 2000; 8 ( 1 ) : 42.
  • 8Raphael SJ, McKeown-Eyssen G, Asa SL. High-molecular-weight cytokeratin and cytokeratin-19 in Me diagnosis of thyroid tumors. Mod Pathol, 1994; 7(3):295.
  • 9Henzen Logmans SC, Mullink H, Ramaekers FC, et al.Expression of cytokeratins and vimentin in epithelial cells of normal and pathologic thyroid tissue. Virchows Arch A Pathol Anat Histopathol, 1987; 410(4):347.
  • 10Vialc G, Dell Orto P, Coggi G,et al. Co-expression of cytokeratins and vimentin in normal and discased thyroid glands : lack of diagnostic utility of vimentin immunostaiing.Am J Surg Pathol, 1989; 13(12):1034.

共引文献58

同被引文献33

  • 1Steinberg SS.诊断外科病理学上卷.回允中,译.3版.北京:北京大学医学出版社,2003:535.
  • 2Ronald AD,Rieardo VL,Philipp UH,et al.World Health Organization classification of tumours:pathology and genetics of tumours of endocrine organs.United Kingdom and Europe:Oxford University Press,2004:57-66.
  • 3Miettinen M,Rovatieh AJ,Karkkainent P,et al.Keratin suhsets in papilary and follicular thyroid lesions:a paraffin.section analysis with diagnostic implications.Vichows Arch,1997,16:407-431.
  • 4Hirokawa M,Horiguchi H,Wakatsuki S,et al.Intranodal benign thyroid tissue ;signifieanee of HBME-1 in differentiation from metastatic papillary thyroid carcinoma.APMIS,2001,109:875-880.
  • 5Ziadi S,Trimeehe M,Zermani R,et al.Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antilbodies in thyroid pathology:a retrospective study of 163 eases.Tunis med,2005,83:274-278.
  • 6Liberman E,Weider N.Papillary and follicular neoplasms of the thyroid gland.Differential immunohistochemieal staining with highmoleeular-weight keratin and involuerin.Appl Immunohistochem Mol Morphol,2000,8:42-48.
  • 7Miettinen M, Rovatich AJ, Karkkainent P, et al. Keratin subsets in papilary and follicular thyroid lesions: A parafin section analysis with diagnostic implications [J] . Vichows Arch, 1997: 431-437.
  • 8Cheung C C, Ezzat S, Free man J L, et al.Immunohistochemical diagnosis of papillary thyroid carcinoma[J].Mod Pathol, 2001, 14 ( 3 ): 338-342.
  • 9Rapheal S J, Mckeown-Eyssen G, Asa S L.High-molecular weight cytokeratin and cytokeratin 19 in the diagnosis of thyroid tumor[J].Mod Pathol, 1994, 7 (10) : 295-301.
  • 10Baloch Z W, Abraham S, Roberts S, et al.Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility[J].Hum Pathol, 1999, 30 (10): 1166.

引证文献4

二级引证文献10

承德医学院学报
2007年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部